Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 21, 2015 9:56 PM ET

Pharmaceuticals

Company Overview of Dermira, Inc.

Company Overview

Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe plaque psoriasis; DRM04, a small-molecule anticholinergic product that has completed a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage progra...

275 Middlefield Road

Suite 150

Menlo Park, CA 94025

United States

Founded in 2010

34 Employees

Phone:

650-421-7200

Key Executives for Dermira, Inc.

Dermira, Inc. does not have any Key Executives recorded.

Dermira, Inc. Key Developments

Dermira, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Dermira, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, loss from operations was $6,782,000 against $6,692,000 last year. Net loss was $6,727,000 compared to $6,714,000 a year ago. Net loss per basic and diluted share was $0.29 against $7.56 last year. Revenue for the quarter ended December 31, 2014 was $7.3 million. For the year ended, loss from operations was $31,698,000 against $22,303,000 last year. Net loss was $31,875,000 compared to net loss of $22,350,000 last year. Net loss per basic and diluted share was $4.96 against $27.03 last year. Revenue for the year ended December 31, 2014 was $7.3 million. For the year 2015, the company expects non-GAAP operating expenses for 2015, excluding the impact of stock-based compensation expense, to be in the range of $80 million to $85 million and to have approximately $90 million in cash and cash equivalents and investments as of year-end 2015.

Dermira, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:40 AM

Dermira, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Thomas G. Wiggans, Co-Founder, Chairman and Chief Executive Officer.

Dermira, Inc. Presents Clinical Data from Its Successful DRM01 Phase 2a Trial in Patients with Facial Acne Vulgaris

Dermira, Inc. announced the presentation of clinical data from its successful DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and non-inflammatory lesion counts and an improvement in the Investigator's Global Assessment (IGA) of acne, were met with statistical significance. DRM01 was generally well tolerated with no reported serious treatment-related adverse events. These results were presented during the Late-Breaking Research in Dermatology Forums at the American Academy of Dermatology (AAD) Annual Meeting on March 20, 2015 in San Francisco. This was the first presentation of DRM01 data at a medical meeting. DRM01 Phase 2a Trial Design and Results: This Phase 2a clinical trial was a randomized, multi-center, double-blind, vehicle-controlled study that enrolled 108 patients with moderate or severe acne. Inclusion criteria required a minimum of 20 inflammatory lesions and 20 non-inflammatory lesions and an IGA score of three or greater on a five-point scale that ranges from a score of zero, representing clear skin, to a score of four, representing severe disease. Patients were instructed to apply either DRM01 at a concentration of 7.5% or vehicle to the face twice daily for 12 weeks. A total of 53 subjects were randomized to receive DRM01, and the other 55 were randomized to receive vehicle only. The primary efficacy endpoints used in this trial consisted of absolute changes from baseline to week 12 in the numbers of inflammatory and non-inflammatory lesions and the proportion of patients with at least a two-grade improvement from baseline to week 12 in IGA score. DRM01 demonstrated statistically significant improvements from baseline to week 12 relative to vehicle in all primary efficacy endpoints. The number of inflammatory lesions in patients treated with DRM01 was reduced by an average of 19.3 compared to 13.3 in patients who received the vehicle only (p=0.0003), or an average percentage reduction of 63.9% and 45.9%, respectively (p=0.0006). The number of non-inflammatory lesions in patients treated with DRM01 was reduced by an average of 19.9 compared to 11.2 in patients who received the vehicle only (p=0.0032), or an average percentage reduction of 48.1% and 28.8%, respectively (p=0.0025). At the end of the 12-week treatment period, 24.5% of patients (13/53) who received DRM01 achieved a successful improvement in the IGA score (minimum two-grade improvement), in comparison with 7.3% of patients (4/55) who received the vehicle only (p=0.0070). DRM01 was well-tolerated with adverse events mild or moderate in severity. The most frequently reported adverse event was nasopharyngitis, which was reported in 13 (24.5%) of the patients treated with DRM01 and in 7 (12.7%) of the patients who received vehicle and which was considered unrelated to treatment. Application-site conditions, which are frequently observed in most clinical trials of topical products, also were observed. No treatment-related serious adverse events were reported.

Similar Private Companies By Industry

Company Name Region
St. Jon Laboratories Inc. United States
Zenith Laboratories, Inc. United States
Escoublac Inc. United States
PolyMedica Pharmaceuticals (U.S.A.), Inc. United States
Nutra Manufacturing, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 19, 2014
--
Private Placement
August 15, 2014
--
Private Placement
July 3, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dermira, Inc., please visit www.dermira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.